enGene Therapeutics Inc.
ENGN Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2022–FY2025
Last close · Oct 23, 2026
$1.56
1.3%
Revenue
Total sales reported in the income statement.
—
vs prior year
Operating margin
Operating income as a share of revenue.
—
Net income
Profit after all expenses, interest and tax.
−$117M
Free cash flow
Cash from operations minus capital spending.
−$101M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
$109M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
0.6x
On $2.43 EPS (TTM)
What enGene Therapeutics Inc. does
No business description yet.
- Legal name
- enGene Therapeutics Inc.
- Fiscal year ends
- October 31, 2025
- Latest annual report
- 10-K · Dec 22, 2025
- Accession · CIK
- 0001193125-25-328743
0001980845
Revenue and margins
enGene Therapeutics Inc. had — of revenue in fiscal 2025.
FY22
Revenue —
FY23
Revenue —
FY24
Revenue —
FY25
Revenue —
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net —
FCF —
FY25
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
From fiscal 2022 to 2025, diluted EPS grew −62.7% a year. Loss periods are shown in red.
FY22
Net income −$24.5M
FY23
Net income −$99.9M
FY24
Net income −$55.1M
FY25
Net income −$117M
Q4 '23
Net income −$82.5M
Q1 '24
Net income −$10.7M
Q2 '24
Net income −$15.0M
Q3 '24
Net income −$14.1M
Q4 '24
Net income −$15.3M
Q1 '25
Net income −$24.6M
Q2 '25
Net income −$25.8M
Q3 '25
Net income −$29.0M
Q4 '25
Net income −$37.9M
Q1 '26
Net income −$29.8M
Q2 '26
Net income −$30.2M
Q3 '26
Net income −$32.5M
FY22
Diluted EPS $44.30
FY23
Diluted EPS $151.22
FY24
Diluted EPS $1.46
FY25
Diluted EPS $2.29
Q4 '23
Diluted EPS $120.08
Q1 '24
Diluted EPS $0.46
Q2 '24
Diluted EPS $0.38
Q3 '24
Diluted EPS $0.32
Q4 '24
Diluted EPS $0.30
Q1 '25
Diluted EPS $0.48
Q2 '25
Diluted EPS −$0.51
Q3 '25
Diluted EPS −$0.57
Q4 '25
Diluted EPS $2.89
Q1 '26
Diluted EPS $0.44
Q2 '26
Diluted EPS −$0.43
Q3 '26
Diluted EPS −$0.47
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY22
Return on capital —
Return on equity —
Return on assets −102.3%
FY23
Return on capital —
Return on equity —
Return on assets −180.2%
FY24
Return on capital —
Return on equity −32.0%
Return on assets −27.7%
FY25
Return on capital —
Return on equity −53.3%
Return on assets −44.0%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$101M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
FY22
Free cash flow −$17.7M
FY23
Free cash flow −$25.1M
FY24
Free cash flow −$49.2M
FY25
Free cash flow −$101M
Q4 '23
Free cash flow −$6.9M
Q1 '24
Free cash flow −$7.9M
Q2 '24
Free cash flow −$14.3M
Q3 '24
Free cash flow −$7.2M
Q4 '24
Free cash flow −$19.8M
Q1 '25
Free cash flow −$26.0M
Q2 '25
Free cash flow −$23.0M
Q3 '25
Free cash flow −$26.3M
Q4 '25
Free cash flow −$25.4M
Q1 '26
Free cash flow −$29.1M
Q2 '26
Free cash flow −$30.6M
Q3 '26
Free cash flow −$18.9M
FY22
Cash from operations −$17.6M
Capital spending $0.2M
FY23
Cash from operations −$24.7M
Capital spending $0.3M
FY24
Cash from operations −$48.3M
Capital spending $0.9M
FY25
Cash from operations −$99.2M
Capital spending $1.5M
Cash from operations
Capital spending
Q4 '23
Cash from operations −$6.8M
Capital spending $0.1M
Q1 '24
Cash from operations −$7.4M
Capital spending $0.5M
Q2 '24
Cash from operations −$14.2M
Capital spending $0.2M
Q3 '24
Cash from operations −$7.2M
Capital spending $0.0M
Q4 '24
Cash from operations −$19.6M
Capital spending $0.2M
Q1 '25
Cash from operations −$25.7M
Capital spending $0.3M
Q2 '25
Cash from operations −$22.9M
Capital spending $0.0M
Q3 '25
Cash from operations −$25.6M
Capital spending $0.7M
Q4 '25
Cash from operations −$25.0M
Capital spending $0.4M
Q1 '26
Cash from operations −$28.9M
Capital spending $0.2M
Q2 '26
Cash from operations −$30.5M
Capital spending $0.1M
Q3 '26
Cash from operations −$18.9M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
enGene Therapeutics Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 35.3%.
FY22
Dividends —
Buybacks —
FY23
Dividends $0.0M
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.04B
FY25
Diluted shares 0.05B
Balance sheet
Cash, debt and the ratios that show how comfortably enGene Therapeutics Inc. can carry it.
FY22
Cash $20.4M
Debt —
FY23
Cash $81.5M
Debt —
FY24
Cash $238M
Debt —
FY25
Cash $194M
Debt —
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $20.4M | $81.5M | $238M | $194M |
| Interest coverage | −13.7x | −5.3x | −22.3x | −41.1x |
| Current ratio | 4.4x | 16.3x | 16.9x | 6.3x |
| Quick ratio | 4.4x | 16.3x | 16.9x | 6.3x |
| Total assets | $23.9M | $87.0M | $311M | $221M |
| Total liabilities | $47.4M | $14.5M | $38.6M | $53.8M |
| Shareholders' equity | −$76.6M | $72.5M | $273M | $168M |
| Net debt (− = net cash) | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — |
| Current ratio rose | — | ✓ | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✕ | ✕ |
| Gross margin rose | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 | — / 6 |
| Accruals ratio | −28.7% | −135.6% | −3.4% | −6.8% |
| Altman Z'' | −15.95 | 1.81 | 8.31 | −0.92 |
4 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | $15.5M | $16.5M | $38.3M | $94.5M |
| Operating income | −$19.4M | −$26.1M | −$62.3M | −$123M |
| Interest expense | $1.4M | $5.0M | $2.8M | $3.0M |
| Pretax income | −$24.4M | −$99.9M | −$55.2M | −$117M |
| Income tax | $0.0M | $0.0M | −$0.0M | $0.0M |
| Net income | −$24.5M | −$99.9M | −$55.1M | −$117M |
| Net income to common | −$29.0M | −$105M | −$55.1M | −$117M |
| Diluted EPS | $44.30 | $151.22 | $1.46 | $2.29 |
| Diluted shares | 0.00B | 0.00B | 0.04B | 0.05B |
| Cash flow | ||||
| Cash from operations | −$17.6M | −$24.7M | −$48.3M | −$99.2M |
| Capital expenditure | $0.2M | $0.3M | $0.9M | $1.5M |
| Free cash flow | −$17.7M | −$25.1M | −$49.2M | −$101M |
| Depreciation and amortization | $0.2M | $0.2M | $0.3M | $0.5M |
| Stock-based compensation | $0.1M | $3.5M | $5.3M | $9.6M |
| Dividends paid | — | $0.0M | — | — |
| Dividends and buybacks | — | $0.0M | — | — |
| Balance sheet | ||||
| Cash and short-term investments | $20.4M | $81.5M | $238M | $194M |
| Current assets | $22.6M | $85.4M | $247M | $201M |
| Current liabilities | $5.1M | $5.3M | $14.7M | $32.0M |
| Property and equipment, net | $0.4M | $0.6M | $1.2M | $2.5M |
| Total assets | $23.9M | $87.0M | $311M | $221M |
| Total liabilities | $47.4M | $14.5M | $38.6M | $53.8M |
| Shareholders' equity | −$76.6M | $72.5M | $273M | $168M |
| Returns | ||||
| Return on capital employed | −103.3% | −31.9% | −21.0% | −65.0% |
| Return on equity | — | — | −32.0% | −53.3% |
| Return on assets | −102.3% | −180.2% | −27.7% | −44.0% |
| Return on tangible equity | — | −144.5% | −20.2% | −69.9% |
| Growth | ||||
| EPS growth | — | 241.4% | −99.0% | 56.8% |
| Share count change | — | 5.7% | 5,355.1% | 35.3% |
| Financial health | ||||
| Interest coverage | −13.7x | −5.3x | −22.3x | −41.1x |
| Current ratio | 4.4x | 16.3x | 16.9x | 6.3x |
| Quick ratio | 4.4x | 16.3x | 16.9x | 6.3x |
| Quality scores | ||||
| Altman Z'' | −16.0 | 1.8 | 8.3 | −0.9 |
| Accruals ratio | −28.7% | −135.6% | −3.4% | −6.8% |
Source: SEC EDGAR XBRL filings (CIK 0001980845). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.